Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;23(9):1624-1635.
doi: 10.1038/s41436-021-01182-1. Epub 2021 May 26.

UBA2 variants underlie a recognizable syndrome with variable aplasia cutis congenita and ectrodactyly

Affiliations

UBA2 variants underlie a recognizable syndrome with variable aplasia cutis congenita and ectrodactyly

Rhonda E Schnur et al. Genet Med. 2021 Sep.

Abstract

Purpose: The human chromosome 19q13.11 deletion syndrome is associated with a variable phenotype that includes aplasia cutis congenita (ACC) and ectrodactyly as specific features. UBA2 (ubiquitin-like modifier-activating enzyme 2) lies adjacent to the minimal deletion overlap region. We aimed to define the UBA2-related phenotypic spectrum in humans and zebrafish due to sequence variants and to establish the mechanism of disease.

Methods: Exome sequencing was used to detect UBA2 sequence variants in 16 subjects in 7 unrelated families. uba2 loss of function was modeled in zebrafish. Effects of human missense variants were assessed in zebrafish rescue experiments.

Results: Seven human UBA2 loss-of-function and missense sequence variants were detected. UBA2-phenotypes included ACC, ectrodactyly, neurodevelopmental abnormalities, ectodermal, skeletal, craniofacial, cardiac, renal, and genital anomalies. uba2 was expressed in zebrafish eye, brain, and pectoral fins; uba2-null fish showed deficient growth, microcephaly, microphthalmia, mandibular hypoplasia, and abnormal fins. uba2-mRNAs with human missense variants failed to rescue nullizygous zebrafish phenotypes.

Conclusion: UBA2 variants cause a recognizable syndrome with a wide phenotypic spectrum. Our data suggest that loss of UBA2 function underlies the human UBA2 monogenic disorder and highlights the importance of SUMOylation in the development of affected tissues.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests:

RES, IMW, MJGS, LR and JJ are employees of GeneDx, Inc., Gaithersburg, MD. The other authors declare no competing interests.

Figures

Figure 1:
Figure 1:. a. Clinical phenotypes and b. Pedigrees associated with UBA2-related syndrome.
a. Family 1, III-2: A. prominent forehead, high hairline, discolored peg-shaped teeth with gap between upper incisors, cleft chin B. low set ear with simple cartilaginous pattern C. diminished distal flexion creases D. brachydactyly, mild 2–3 syndactyly, clinodactyly of the 4th toe. Family 1, IV-4: E. prominent forehead, high hairline, cleft chin, mildly down-slanted palpebral fissures F. ACC G. repaired ectrodactyly, hypoplastic distal flexion creases H. ichthyosis Family 3, I-1: I. tall forehead, hypertelorism, broad nasal root, mild micrognathia J. ACC Family 3, II-1: K. tall forehead, hypertelorism, broad nasal root, thin upper lip, medial eyebrow flare L. ACC Family 3, II-2: M. facial features N. supernumerary nipple (arrow) Family 3, III-1: O. tall forehead, low-set ears, micrognathia P. ACC Family 6, II-1 Q. high forehead, hypertelorism, bilateral epicanthal folds R, S. bilateral 2–3 finger syndactyly, camptodactyly T. bilateral ectrodactyly of the feet b. Affected individuals are shown as filled symbols. Genotypes are shown below each individual who was genotyped. c. Percentages of different clinical features variably expressed in UBA2-affected individuals based on available data. Previously reported UBA2 patients are also included in the percentages.
Figure 2:
Figure 2:. UBA2 syndrome-associated variants and molecular modeling.
a. Schematic representation of the UBA2 gene. Exons are shown in brown color boxes; introns and 3’ and 5’ UTRs are in light grey and purple, respectively. Newly reported UBA2 missense and loss-of-function variants are shown in red and green, respectively, while blue is used to represent previously reported UBA2 variants. b. Schematic representation of UBA2 protein domains. The UBA2 protein domain carrying catalytically active sites of ubiquitin-activating enzyme is shown in light green. This domain has putative active sites to bind ATP, substrate, and zinc with the last of five conserved cysteine residues playing an important role in ubiquitin thioester complex formation. UBA2-C (C-terminus) and UAE-UbL (ubiquitin-like) domains are shown in pink and blue, representing the C-terminus of UBA2 protein. UAE-UbL is structurally similar to ubiquitin and is involved in E1-SUMO-thioester transfer to E2 conjugation protein. The amino acid changes for the aforementioned variants are shown in the same color scheme as Figure 2B. c. Amino acid sequence alignments of the human UBA2 protein across different species at each of the residues reported with missense variants. d. Molecular modeling of human UBA2 protein. Secondary structure helix, strand and coil regions are shown in purple, yellow and cyan blue shades, respectively. Forest green color is used to show residues of interest in proteins with WT and missense changes and the ATP molecule is shown in brick red color. Blue color shows regions of hydrogen bonding and light pink shows residues involved in hydrogen bond formation with residues of interest. The distances to nearby residues are shown by dashed yellow lines. Last panel: UBA2 and UBC9 are shown in hot pink and cyan blue color, respectively. As per molecular modeling predictions, p.Gly24Val: Glycine is flexible enough to maintain torsion angles and is buried in the protein core to maintain local secondary structure. p.Asn56Thr. Introducing a smaller but more hydrophobic residue at Asparagine 56 results in an empty space in the protein core and subsequent loss of hydrogen bonding with Asp53. p.Arg122Gly: The typical Arginine 122 residue is involved in hydrogen bonding with Asn118, Gly138 and Ser139. Replacement with Glycine is predicted to disrupt this array.
Figure 3:
Figure 3:. Severe dysmorphic features in embryonic uba2−/− zebrafish.
a-b. Dorsal and lateral views of uba2 zebrafish at 8 dpf. Compared to WT controls, mutant lines showed aberrant head development with small eyes and hydrocephalus. c. Bar graph representing the percentage of uba2−/− zebrafish with gross morphological defects. d. Survival curve showing the number of live fish over the course of 21 days. WT and heterozygous fish showed similar death curves, but homozygous fish had steeper death curves with 100% mortality by day 12. PF (pectoral fins), T (tail), B (brain), F (craniofacial) and SB (swim bladder).
Figure 4:
Figure 4:. Cranial cartilage patterns observed in uba2−/− zebrafish and rescue of uba2 mutant phenotype with human UBA2 mRNA.
a-b. Brightfield ventral and lateral views of cartilage stained uba2 in wild type and homozygous mutant fish are shown in top and bottom panels, respectively. Closeups of pectoral fin cartilage phenotype are shown in inserts in the bottom panel highlighted by black dashed boxes on lateral views. an (anterior), mk (Meckel’s cartilage), pq (palatoquadrate), ep (ethmoid plate), ch (ceratohyal), h (hypohyal), cb (ceratobranchials 1–4), hs (hyosymplectic). c. Z-stack images of uba2 zebrafish median fins stained with Col2a (green), Rhodamine-Phalloidin (red) and Dapi (blue). Arrows are used to show the gaps between actinotrichia fibers. Scale bar: 50 μm. d. Suppression of uba2 in zebrafish produces an abnormal phenotype which is classified into three categories. e. Proportions of uba2−/− zebrafish embryos representing each phenotype category after injecting with WT or mutation harboring human UBA2 mRNA. Landmark abbreviations: Nor St (normal structure), Ab (abnormal) and ns (not significant). Chi Square test p-values are shown above the phenotypes for each rescue experiment.

References

    1. Abe KT, Rizzo I, Coelho ALV, Sakai N Jr., Carvalho DR, Speck-Martins CE. 19q13.11 microdeletion: Clinical features overlapping ectrodactyly ectodermal dysplasia-clefting syndrome phenotype. Clin Case Rep. 2018;6:1300–1307. - PMC - PubMed
    1. Chowdhury S, Bandholz AM, Parkash S, et al.Phenotypic and molecular characterization of 19q12q13.1 deletions: a report of five patients. Am J Med Genet A. 2014;164A:62–69. - PubMed
    1. Gana S, Veggiotti P, Sciacca G, et al.19q13.11 cryptic deletion: description of two new cases and indication for a role of WTIP haploinsufficiency in hypospadias. Eur J Hum Genet. 2012;20:852–856. - PMC - PubMed
    1. Malan V, Raoul O, Firth HV, et al.19q13.11 deletion syndrome: a novel clinically recognisable genetic condition identified by array comparative genomic hybridisation. J Med Genet. 2009;46:635–640. - PubMed
    1. Melo JB, Estevinho A, Saraiva J, Ramos L, Carreira IM. Cutis Aplasia as a clinical hallmark for the syndrome associated with 19q13.11 deletion: the possible role for UBA2 gene. Mol Cytogenet. 2015;8:21. - PMC - PubMed

Publication types

Substances

Supplementary concepts

LinkOut - more resources